InnovaGel Recalls Subpotent Diphenhydramine HCl Softgel Capsules
InnovaGel is recalling approximately 7.9 million subpotent Diphenhydramine HCl 25 mg softgel capsules distributed in New York.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates a low risk of adverse health consequences, and the issue is a subpotent product rather than a contamination or labeling error involving allergens.
Plain-English summary
InnovaGel is voluntarily recalling approximately 7,920,177 Diphenhydramine HCl 25 mg softgel gelatin capsules. The product is sold in 15,000-count bulk drums and is manufactured by aenova/Swiss Caps USA, Inc. The recall was initiated on January 5, 2017, and was classified as Class III by the FDA.
The reason for the recall is that the capsules are subpotent, meaning they do not contain the full amount of the active ingredient stated on the label. The affected product is identified by Product Code MSU0048P and NDC 6897080284. Specific batch numbers include 1404811, 1409802, 1502817, 1504808, 1509810, 1511802, and 1603801, all with an expiration date of December 12, 2018.
The affected capsules were distributed only in New York. The recall status is currently terminated. Consumers and healthcare providers should check their inventory for these specific batch numbers and contact the recalling firm for further instructions.
The recalled product
- Product
- Diphenhydramine HCl 25 mg, Softgel Gelatin Capsule, 15,000-count bulk drums, aenova/Swiss Caps USA, Inc., 14193 S.W. 119th Avenue, Miami, FL 33186, Product Code MSU0048P, NDC 6897080284
- Manufacturer
- InnovaGel
- Category
- Drug — Antihistamine
- Hazard
- Affected units
- 7,920,177
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Batch #: 1404811
- 1409802
- 1502817
- 1504808
- 1509810
- 1511802
- 1603801
- Exp. 12/12/2018.
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 2 recalled by InnovaGel under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · InnovaGel
See all →- LowInnovaGel Recalls Subpotent Dye Free Allergy Softgel Gelatin Capsules
FDA (Drugs) · 2017-04-26
Same hazard · subpotent drug
See all →- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
Similar recalls
- LowDiphenhydramine HCl Capsules Recalled Due to Wrong ID Imprinting
FDA (Drugs) · 2025-01-22
- SevereActavis Recalls Subpotent Vancomycin Hydrochloride Capsules Nationwide
FDA (Drugs) · 2014-06-25
- HighIcosapent ethyl capsules recalled as subpotent after capsule contents leaked
FDA (Drugs) · 2026-01-28
- ModerateDiphenhydramine HCl Capsules Recalled Due to Wrong Imprinting
FDA (Drugs) · 2025-01-22
- LowDiphenhydramine HCl 50 mg Capsules Recalled Due to Incorrect ID Imprinting
FDA (Drugs) · 2025-01-22
- ModerateP & L Development Recalls Subpotent Diphenhydramine HCl Allergy Softgels
FDA (Drugs) · 2017-05-10